Cerevance Media Center

Current News

April 19, 2022

Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.

READ FULL

March 31, 2022

Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism

Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.

READ FULL

January 25, 2022

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

READ FULL

September 8, 2021

Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors

Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

September 23, 2024

Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024

Date:
Tuesday, October 1, 2024
Time:
2:15 – 3:00 PM EDT
Location:
Boston, MA
Media:
Panel Discussion
Read full

May 20, 2024

Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention

Date:
Tuesday, June 4, 2024
Time:
11 am – 12 pm, PT
Location:
San Diego, CA
Media:
Panel Discussion
Read full

May 9, 2024

Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders

Date:
Monday, May 20, 2024
Time:
9:35 – 10:20am
Location:
Lisbon, Portugal
Media:
Oral Presentation
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

June 27, 2024

CryoEM Structure of the human THIK-1 K2P K+ Channel Reveals a Lower ‘Y-gate’ Regulated by Lipids and Anaesthetics

Rödström, K. E.J., Eymsh, B., Proks, P., Hayre, M. S., Madry, C., Rowland, A., Newstead, S., Baukrowitz, T., Schewe, M., Tucker, S. J.

Viewview

January 26, 2023

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor

Mu, C., Li, X., Yang, Y., Zhou, Y., Wang, C., Doyle, K.J., Ye, N., Mistry, A., Burli, R.

Viewview

December 1, 2020

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

Sun, H., Monenschein, H., Schiffer, H.H., Reichard, H.A., Kikuchi, S., Hopkins, M., Macklin, T.K., Hitchcock, S., Adams, M., Green, J., Brown, J., Murphy, S.T., Kaushal, N., Collia, D.R., Moore, S., Ray, W.J., English, N.M., Carlton, M.B, Brice, N.L.

Viewview

February 26, 2024

Differential Contribution of THIK‑1 K+ Channels and P2X7 Receptors to ATP‑Mediated Neuroinflammation by Human Microglia

Rifat, A., Ossola, B., Bürli, R. W. , Dawson, L. A., Brice, N. L., Rowland, A., Lizio, M., Xu, X., Page, K., Fidzinski, P., Onken, J., Holtkamp, M., Heppner, F. L., Geiger, J. R. P., Madry, C.

Viewview

March 21, 2022

The Two Pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation

Drinkall, S., Lawrence, C.B., Ossola, B., Russell, S., Bender, C., Brice, N.L., Dawson, L.A., Harte, M., Brough D.

Viewview

November 21, 2022

Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction

Schneeberger, M., Brice, N.L., Pellegrino, K., Parolar, L., Shaked, J.T., Page, K., Marchildon, F., Barrows, D., Carroll, T.S., Tolpiko, T., Mulligan, V., Barker, D., Glen, A., Newman, R., Ortuño, M.J., Renier, N., Nectow, A.R., Cohen, P., Carlton, M., Heintz, N., Friedman, J.M.

Viewview